Wheezing – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:14 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Wheezing – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of inhaled corticosteroids (beclometasone, fluticasone, budesonide) and salbutamol in children aged 1-6 years with episodic wheezing https://clinicaltrials.eu/trial/study-of-inhaled-corticosteroids-beclometasone-fluticasone-budesonide-and-salbutamol-in-children-aged-1-6-years-with-episodic-wheezing/ Wed, 29 Apr 2026 15:07:34 +0000 https://clinicaltrials.eu/trial/study-of-inhaled-corticosteroids-beclometasone-fluticasone-budesonide-and-salbutamol-in-children-aged-1-6-years-with-episodic-wheezing/ This study focuses on children with episodic expiratory wheezing, a condition where breathing becomes difficult and produces a whistling sound during exhalation. The research examines the effectiveness of different treatment approaches using inhaled medications called corticosteroids and bronchodilators.

The medications being studied include several types of inhaled corticosteroids: beclometasone dipropionate, fluticasone propionate, and budesonide. These are anti-inflammatory medicines that help reduce swelling in the airways. Another medication being tested is salbutamol, a bronchodilator that helps relax and open up the airways to make breathing easier.

The study compares two different ways of using these medications: one approach involves taking corticosteroids daily for at least 6 weeks along with bronchodilators when needed, while the other approach uses these medications only when symptoms appear. The treatment period lasts for 12 months, during which the effects on breathing symptoms and quality of life will be monitored.

]]> Study on Betamethasone Sodium Phosphate to Prevent Asthma in Children with First-time Rhinovirus-induced Wheezing https://clinicaltrials.eu/trial/study-on-betamethasone-sodium-phosphate-to-prevent-asthma-in-children-with-first-time-rhinovirus-induced-wheezing/ Wed, 29 Apr 2026 15:03:18 +0000 https://clinicaltrials.eu/trial/study-on-betamethasone-sodium-phosphate-to-prevent-asthma-in-children-with-first-time-rhinovirus-induced-wheezing/ This clinical trial is focused on children who have experienced their first episode of severe wheezing, which is a type of breathing difficulty often associated with a viral infection called rhinovirus. The study aims to explore whether a treatment using a type of medication known as systemic corticosteroids can help prevent future episodes of wheezing and the development of asthma. The specific medication being tested is called dexamethasone, and it will be compared to a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to determine if these corticosteroids can effectively reduce the risk of recurrent wheezing and asthma in young children. Participants in the study will receive either the dexamethasone treatment or a placebo. The study will monitor the children over a period of time to see how many experience new episodes of wheezing or develop asthma, which is a condition that causes the airways to become inflamed and narrow, making it difficult to breathe.

Throughout the study, researchers will also observe other factors such as the duration and severity of any breathing difficulties, the children’s overall quality of life, and their growth in terms of height and weight. This information will help determine the effectiveness of the treatment in preventing asthma and improving the health outcomes for children who have had a severe wheezing episode due to rhinovirus.

]]> Study on Oral Prednisolone and Sucrose for Treating Wheezing Caused by Rhinovirus in Children Under 2 Years Old https://clinicaltrials.eu/trial/study-on-oral-prednisolone-and-sucrose-for-treating-wheezing-caused-by-rhinovirus-in-children-under-2-years-old/ Wed, 29 Apr 2026 14:30:17 +0000 https://clinicaltrials.eu/trial/study-on-oral-prednisolone-and-sucrose-for-treating-wheezing-caused-by-rhinovirus-in-children-under-2-years-old/ This clinical trial is focused on studying children under 2 years old who experience wheezing caused by a common cold virus known as the rhinovirus. Wheezing is a high-pitched whistling sound made while breathing, often associated with difficulty in breathing. The study aims to determine if a medication called prednisolone sodium phosphate, which is a type of steroid that helps reduce inflammation, can help these children. The treatment involves taking the medication orally, which means it is swallowed in the form of a liquid solution.

During the study, children will receive either the prednisolone sodium phosphate or a placebo, which is a substance with no active medication. The study will last for a short period, and the children will be monitored to see how quickly they recover from wheezing and if they need to stay in the hospital for a shorter time. The goal is to see if the medication helps them get better faster and reduces the need for additional medical care.

Parents and caregivers will be informed about the progress and any changes in the child’s condition throughout the study. The study will also track if the children experience any recurrence of wheezing or other related symptoms over a period of time after the initial treatment. This research is important to find better ways to help young children who suffer from wheezing due to viral infections.

]]> Study on the Effectiveness and Safety of OM-85 for Children Aged 6 Months to 5 Years with Recurrent Wheezing https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-om-85-for-children-aged-6-months-to-5-years-with-recurrent-wheezing/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-om-85-for-children-aged-6-months-to-5-years-with-recurrent-wheezing/ This clinical trial is focused on studying the effects of a treatment called OM-85 in children who experience recurrent wheezing. Recurrent wheezing is a condition where children have repeated episodes of wheezing, which is a high-pitched whistling sound made while breathing. The study will compare the effects of OM-85 with a placebo, which is a substance with no active medication, to see if OM-85 can help reduce the frequency of these wheezing episodes.

The treatment being tested, OM-85, is made from lyophilized bacterial lysates, which are small parts of bacteria that have been dried and processed. These bacterial lysates come from several types of bacteria, including Haemophilus influenzae and Streptococcus pneumoniae. The study aims to determine if taking OM-85 daily can decrease the number of wheezing episodes in children aged 6 months to 5 years over a period of six months.

Participants in the study will be randomly assigned to receive either OM-85 or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The main goal is to see if OM-85 can effectively reduce the rate of wheezing episodes compared to the placebo during the treatment period. Safety and any side effects will also be monitored throughout the study.

]]> Study on the Effects and Safety of Dupilumab for Children Aged 2 to Under 6 with Uncontrolled Asthma or Severe Asthmatic Wheeze https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-dupilumab-for-children-aged-2-to-under-6-with-uncontrolled-asthma-or-severe-asthmatic-wheeze/ Wed, 29 Apr 2026 14:25:50 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-dupilumab-for-children-aged-2-to-under-6-with-uncontrolled-asthma-or-severe-asthmatic-wheeze/ This clinical trial is focused on studying the effects of a medication called dupilumab in young children aged 2 to less than 6 years who have asthma or experience frequent severe wheezing. Asthma is a condition that affects the airways in the lungs, making it difficult to breathe. The study aims to understand how well dupilumab works in reducing severe asthma attacks and to assess its safety over a long period. Participants in the study will receive either dupilumab or a placebo, which is a substance with no active medication, to compare the effects.

The study will be conducted over a period of 52 weeks, during which the children will receive regular injections of dupilumab in a pre-filled syringe. The study will monitor the frequency of severe asthma attacks and any side effects that may occur. The goal is to see if dupilumab can help reduce the number of asthma attacks and improve the overall health and quality of life for these young children.

In addition to dupilumab, the study will also consider other medications that the children might be using, such as ipratropium bromide, salbutamol, beclometasone, fluticasone, montelukast, and salmeterol. These medications are commonly used to manage asthma symptoms and will help provide a comprehensive understanding of how dupilumab fits into the treatment plan for children with asthma. The study will help determine the best ways to manage asthma in young children and improve their breathing and overall well-being.

]]>